logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical turns to CBD sol-gel program to develop possible coronavirus treatment

The technology works by infusing cannabis extracts into water-based sol-gels, which are delivered using a nasal spray applicator

Person wearing medical mask and nursing cap holding a vial of blood labeled 'coronavirus'
Research has suggested that some cannabis extracts may help in the prevention and treatment of the coronavirus

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) announced Monday that the company is working on an extension of its cannabis sol-gel nasal program to address the coronavirus (COVID-19) pandemic. 

The program extension will focus on the expedited development of a CBD sol-gel to potentially reduce the possibility of coronavirus infections.

Shares of PreveCeutical jumped 40% to C$0.035 in Toronto.

The technology works by infusing cannabis extracts into water-based sol-gels, which are delivered using a nasal spray applicator. PreveCeutical has been developing the sol-gel program since 2017 and spent more than $700,00 in research. 

READ: PreveCeutical confirms its first peptide with promising preclinical potential as a non-addictive painkiller

The company is working with partners to create the terms of the program expansion with partners and expects formulation development to begin within the next few weeks. The company isn’t claiming that its product has the ability to eliminate or cure the coronavirus at the time, but if things go to plan, testing could be ready in as little as four months, PreveCeutical said.

Ultimately, PreveCeutical plans to engage with global health agencies to seek fast-track approval of the resulting CBD sol-gel formulation. 

Although the company stressed that no guarantees could be made, it noted in a statement that some research has suggested that certain cannabis extracts may help in the prevention and treatment of the coronavirus. 

PreveCeutical, based in Vancouver, is also advancing non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone, and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: PreveCeutical Medical Inc.

Price: 0.035 CAD

CSE:PREV
Market: CSE
Market Cap: $13.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 15/11/19

2 min read